Search Within

Susan H Korte

Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Department of Medicine (8)
  2. Head and Neck Service (8)
  3. Neuroradiology Service (8)
  4. Radiology, Department of (8)
  5. Solid Tumor Oncology Division (8)
  6. Department of Pathology and Laboratory Medicine (5)

More Groups

People
  1. David Pfister (8)
  2. Eric Sherman (8)
  3. Sofia Haque (8)
  4. Matthew Fury (7)
  5. Alan Ho (5)
  6. Donna Lisa (5)

More People

Years
  1. 2017 (2)
  2. 2013 (1)
  3. 2012 (4)
  4. 2011 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Annals of Oncology (1)
  3. Cancer Chemotherapy and Pharmacology (1)
  4. International Journal of Radiation Oncology, Biology, Physics (1)
  5. Journal of the National Comprehensive Cancer Network (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier Inc. (1)
  3. Harborside Press (1)
  4. Oxford University Press (1)
  5. Springer (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Combination of dabrafenib (DAB)
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Baxi, S. S.; Dunn, L.; Korte, S. H.; Haque, S.; Ghossein, R. A.; Chen, H. X.; Pfister, D. G.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Journal Article

    Dunn, L. A.; Fury, M. G.; Xiao, H.; Baxi, S. S.; Sherman, E. J.; Korte, S.; Pfister, C.; Haque, S.; Katabi, N.; Ho, A. L.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer
    Journal Article

    Fury, M. G.; Lee, N. Y.; Sherman, E.; Ho, A. L.; Rao, S.; Heguy, A.; Shen, R.; Korte, S.; Lisa, D.; Ganly, I.; more...
    International Journal of Radiation Oncology, Biology, Physics (2013)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Meeting Abstract

    Sherman, E. J.; Ho, A. L.; Fury, M. G.; Baxi, S. S.; Haque, S.; Korte, S. H.; Smith-Marrone, S.; Xiao, H.; Ghossein, R. A.; Fagin, J. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I study of everolimus (E) plus weekly cisplatin (CDDP) plus intensity-modulated radiation therapy (IMRT) in head and neck (HN) cancer
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Ho, A. L.; Rao, S. S.; Shen, R.; Korte, S. H.; Lisa, D. M.; Ganly, I.; Katabi, N.; Patel, S. G.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer
    Journal Article

    Fury, M. G.; Sherman, E.; Lisa, D.; Agarwal, N.; Algazy, K.; Brockstein, B.; Langer, C.; Lim, D. ; Mehra, R.; Rajan, S. K.; more...
    Journal of the National Comprehensive Cancer Network (2012)

    Fulltext@MSK | Save
  • A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
    Journal Article

    Fury, M. G.; Sherman, E.; Haque, S.; Korte, S.; Lisa, D.; Shen, R.; Wu, N.; Pfister, D.
    Cancer Chemotherapy and Pharmacology (2012)

    Fulltext@MSK | Save
  • A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m(2) for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Meeting Abstract

    Fury, M. G.; Sherman, E. J.; Lisa, D. M.; Agarwal, N.; Algazy, K. M.; Brockstein, B.; Langer, C. J.; Lim, D.; Mehra, R.; Rajan, S. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save